研究单位:[1]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510060[2]Beijing Tongren Hospital,Beijing,Beijing,China,100730
研究目的:
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural killer/T cell lymphoma.